Tiapride	tiapride	S_chemicals	O
in	in	O	O
levodopa-induced	levodopa-induced	O	O
involuntary	involuntary	O	B_disease
movements	movements	O	I_disease
.	.	O	O

Tiapride	tiapride	S_chemicals	O
,	,	O	O
a	a	O	O
substituted	substituted	O	O
benzamide	benzamide	O	O
derivative	derivative	O	O
closely	closely	O	O
related	related	O	O
to	to	O	O
metoclopramide	metoclopramide	S_chemicals	O
,	,	O	O
reduced	reduced	O	O
levodopa-induced	levodopa-induced	O	O
peak	peak	O	O
dose	dose	O	O
involuntary	involuntary	O	B_disease
movements	movements	O	I_disease
in	in	O	O
16	16	O	O
patients	patients	O	O
with	with	O	O
idiopathic	idiopathic	O	B_disease
Parkinson	parkinson	O	B_disease
's	's	O	I_disease
disease	disease	O	S_disease
.	.	O	O

However	however	O	O
,	,	O	O
an	an	O	O
unacceptable	unacceptable	O	O
increase	increase	O	O
in	in	O	O
disability	disability	O	S_disease
from	from	O	O
Parkinsonism	parkinsonism	O	S_disease
with	with	O	O
aggravation	aggravation	O	O
of	of	O	O
end-of-dose	end-of-dose	O	O
akinesia	akinesia	O	O
led	led	O	O
to	to	O	O
its	its	O	O
cessation	cessation	O	O
in	in	O	O
14	14	O	O
patients	patients	O	O
.	.	O	O

Tiapride	tiapride	S_chemicals	O
had	had	O	O
no	no	O	O
effect	effect	O	O
on	on	O	O
levodopa-induced	levodopa-induced	O	O
early	early	O	O
morning	morning	O	O
of	of	O	O
"	"	O	O
off-period	off-period	O	O
"	"	O	O
segmental	segmental	O	O
dystonia	dystonia	O	S_disease
.	.	O	O

These	these	O	O
results	results	O	O
fail	fail	O	O
to	to	O	O
support	support	O	O
the	the	O	O
notion	notion	O	O
that	that	O	O
levodopa-induced	levodopa-induced	O	O
dyskinesias	dyskinesias	O	S_disease
are	are	O	O
caused	caused	O	O
by	by	O	O
overstimulation	overstimulation	O	O
of	of	O	O
a	a	O	O
separate	separate	O	O
group	group	O	O
of	of	O	O
dopamine	dopamine	B_chemicals	O
receptors	receptors	I_chemicals	O
.	.	O	O

